Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCell InstituteTSE:7096 -0.78%68 Days Payable is 11.40 as of Mar. 2026, which is 14% below its 10-year median of 13.20. GuruFocus rates TSE:7096 with a GF Score™ of 68/100 and a GF Value™ of 円1,837.46 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 708 Biotechnology companies, StemCell Institute ranks worse than 95.06% on this metric.
The historical rank and industry rank for StemCell Institute's Days Payable or its related term are showing as below:
TSE:7096'
s Days Payable Range Over the Past 10 Years
Min: 9.78 Med: 13.2 Max: 14.53
Current: 10.94
During the past 9 years, StemCell Institute's highest Days Payable was 14.53. The lowest was 9.78. And the median was 13.20.
TSE:7096's Days Payable is ranked worse than 95.06% of 708
companies
in the Biotechnology industry
Industry Median: 111.165
vs TSE:7096: 10.94
StemCell Institute's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (11.40).
It may suggest that StemCell Institutedelayed paying its suppliers.
The historical data trend for StemCell Institute's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, StemCell Institute's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's Days Payable distribution charts can be found below:
* The bar in red indicates where StemCell Institute's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
StemCell Institute's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCell Institute (TSE:7096) has a Days Payable of 11.40 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on StemCell Institute and its competitors. This is 14% below median its historical median of 13.20. Over the past decade, StemCell Institute's Days Payable has ranged from 9.78 to 14.53. According to the industry distribution chart, StemCell Institute ranks #673 out of 708 companies in the Biotechnology industry, placing it in the top 95.1%.
Is StemCell Institute's Days Payable too high?
StemCell Institute's current Days Payable of 11.40 is 14% below median its 10-year median of 13.20. Over the past 10 years, this metric has ranged from a low of 9.78 to a high of 14.53. The Biotechnology industry median Days Payable is 111.17. StemCell Institute's value of 11.40 is 89.7% below this industry median. Based on the distribution chart, StemCell Institute ranks #673 out of 708 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, StemCell Institute has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #673 out of 708 companies for Days Payable. This places StemCell Institute in the lower half of its industry. The industry median Days Payable is 111.17. StemCell Institute's value of 11.40 is 89.7% below this benchmark. Historically, StemCell Institute's own Days Payable has ranged from 9.78 to 14.53 over the past decade. While the company's 10-year median is 13.20 vs. the industry median of 111.17, StemCell Institute has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCell Institute's current Days Payable of 11.40 is 89.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on StemCell Institute and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCell Institute's current Days Payable is 11.40, which is 14% below median its own 10-year median of 13.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,837.46, compared to a current price of 円766.00 — trading 58.3% below its estimated fair value. The current Days Payable is 11.40, which is 14% below median its 10-year median of 13.20 and 89.7% below the Biotechnology industry median of 111.17. StemCell Institute's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Days Payable is 11.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円766.00 is trading 58.3% below its estimated GF Value™ of 円1,837.46.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
Days Payable: 11.40 (14% below median its 10-year median of 13.20)
GF Value™: 円1,837.46 vs. price of 円766.00 (58.3% below fair value)
Industry Position: 89.7% below the Biotechnology median (#673 of 708)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
68GF Score
Get the complete analysis for TSE:7096
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
